A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer
M. P. Kolinsky, P. Rescigno, D. Bianchini, Z. Zafeiriou, N. Mehra, J. Mateo, V. Michalarea, R. Riisnaes, M. Crespo, I. Figueiredo, S. Miranda, D. Nava Rodrigues, P. Flohr, N. Tunariu, U. Banerji, R. Ruddle, A. Sharp, J. Welti, M. Lambros, S. CarreiraF. I. Raynaud, K. E. Swales, S. Plymate, J. Luo, H. Tovey, N. Porta, R. Slade, L. Leonard, E. Hall, J. S. de Bono
Dive into the research topics of 'A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.